Cigna Corp. (CI) Tops Q4 EPS by 9c, Revenues Beat; Offers FY19 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Cigna Corp. (CI) Tops Q4 EPS by 9c, Revenues Beat; Offers FY19 EPS Guidance Below Consensus
January 31, 2019 5:49 PM EST
Today's After-Hours Movers
Symantec (NASDAQ: SYMC) 6.3% HIGHER; reported Q3 EPS of $0.44, $0.05 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.18 billion. Symantec sees Q4 2019 EPS of $0.37-$0.41, versus the consensus of $0.38. Symantec sees Q4 2019 revenue of $1.19-1.22 billion, versus the consensus of $1.21 billion. Symantec sees FY2019 EPS of $1.57-$1.61, versus the consensus of $1.54. Symantec sees FY2019 revenue of $4.76-4.79 billion, versus the consensus of $4.74 billion.
Digi Int'l (NASDAQ: DGII)... More
January 31, 2019 4:38 PM EST
On Thursday, Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson proposed a rule to lower prescription drug prices and out-of-pocket costs by encouraging manufacturers to pass discounts directly on to patients and bringing new transparency to prescription drug markets.
Every day, Americansparticularly our seniorspay more than they need to for their prescription drugs because of a hidden system of kickbacks to middlemen. President Trump is proposing to end this era of backdoor deals in the drug industry, bring real transparency to drug markets, and deliver savings directly to patients when they walk into... More
